Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
On August 7, 2014, an increase in the notional allocation of GSK American Depositary Shares (ADSs) occurred within the GSK 401K plan following the revaluation of the cash element of the notional investment. The transaction price was $46.35 per ADS. The specific allocations were:
- Directors/PDMRs: Mrs D P Connelly (2 ADSs), Mr W C Louv (26 ADSs), Dr M M Slaoui (19 ADSs).
- Connected Persons: Dr K Slaoui (16 ADSs).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the impact of the 401K plan revaluation on director and connected person holdings as of August 7, 2014.
- Confirm the transaction price of $46.35 per ADS aligns with market data for that date.
- Note that this filing contains no financial performance data; refer to Form 20-F for comprehensive financial metrics.